ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P04637


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name P53_HUMAN
Primary accession number P04637
Secondary accession numbers Q15086 Q15087 Q15088 Q16535 Q16807 Q16808 Q16809 Q16810 Q16811 Q16848 Q86UG1 Q8J016 Q99659 Q9BTM4 Q9HAQ8 Q9NP68 Q9NPJ2 Q9NZD0 Q9UBI2 Q9UQ61
Integrated into Swiss-Prot on August 13, 1987
Sequence was last modified on July 22, 2008 (Sequence version 3)
Annotations were last modified on    June 16, 2009 (Entry version 160)
Name and origin of the protein
Protein name Cellular tumor antigen p53
Synonyms Tumor suppressor p53
Phosphoprotein p53
Antigen NY-CO-13
Gene name
Name: TP53
Synonyms: P53
From
Homo sapiens (Human) [TaxID: 9606] 
Taxonomy Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=4006916 [NCBI, ExPASy, EBI, Israel, Japan]
Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
"Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.";
EMBO J. 4:1251-1255(1985).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT GLY-76.
PubMed=2946935 [NCBI, ExPASy, EBI, Israel, Japan]
Lamb P., Crawford L.;
"Characterization of the human p53 gene.";
Mol. Cell. Biol. 6:1379-1385(1986).
[3]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3894933 [NCBI, ExPASy, EBI, Israel, Japan]
Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
"Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.";
Mol. Cell. Biol. 5:1601-1610(1985).
[4]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=3025664 [NCBI, ExPASy, EBI, Israel, Japan]
Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., Rotter V.;
"Molecular basis for heterogeneity of the human p53 protein.";
Mol. Cell. Biol. 6:4650-4656(1986).
[5]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
DOI=10.1016/0378-1119(88)90196-5; PubMed=2905688 [NCBI, ExPASy, EBI, Israel, Japan]
Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P., Georgiev G.P.;
"A variation in the structure of the protein-coding region of the human p53 gene.";
Gene 70:245-252(1988).
[6]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
PubMed=6396087 [NCBI, ExPASy, EBI, Israel, Japan]
Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L., Benchimol S.;
"Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.";
EMBO J. 3:3257-3262(1984).
[7]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SPORADIC CANCERS.
PubMed=1915267 [NCBI, ExPASy, EBI, Israel, Japan]
Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
"p53 is frequently mutated in Burkitt's lymphoma cell lines.";
EMBO J. 10:2879-2887(1991).
[8]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
PubMed=8316628 [NCBI, ExPASy, EBI, Israel, Japan]
Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D., Mirzayans R.;
"Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.";
Radiat. Res. 134:349-354(1993).
[9]
NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH WWOX.
DOI=10.1074/jbc.M007140200; PubMed=11058590 [NCBI, ExPASy, EBI, Israel, Japan]
Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., Zevotek N.;
"Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity.";
J. Biol. Chem. 276:3361-3370(2001).
[10]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Chumakov P.M., Almazov V.P., Jenkins J.R.;
Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
[11]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
Rozemuller E.H., Tilanus M.G.J.;
"P53 genomic sequence. Corrections and polymorphism.";
Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
[12]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND ALA-366.
NIEHS SNPs program;
Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
[13]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
PubMed=11023613 [NCBI, ExPASy, EBI, Israel, Japan]
Anderson C.W., Allalunis-Turner M.J.;
"Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8.";
Radiat. Res. 154:473-476(2000).
[14]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-273 AND SER-309.
Azuma K., Shichijo S., Itoh K.;
"Identification of a tumor-rejection antigen recognized by HLA-B46 restricted CTL.";
Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
[15]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-278.
TISSUE=Kidney;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[16]
NUCLEOTIDE SEQUENCE [MRNA] OF 1-379, AND VARIANTS ASN-139 AND PRO-155.
TISSUE=Lung carcinoma;
DOI=10.1073/pnas.2536558100; PubMed=14660794 [NCBI, ExPASy, EBI, Israel, Japan]
Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L., Varga J.L.;
"Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.";
Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
[17]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
Pan X.L., Zhang A.H.;
"Study on the effect of tumor suppressor gene p53 in arsenism patients.";
Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
[18]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
TISSUE=Blood;
Nimri L.F., Owais W., Momani E.;
"Detection of P53 gene mutations and serum p53 antibodies associated with cigarette smoking.";
Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
[19]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
TISSUE=Ovarian adenocarcinoma;
Filippini G., Soldati G.;
Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
[20]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
TISSUE=Glial cell, and Glial tumor;
Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N., Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
"Mutation detection utilizing a novel PCR approach for amplification of the p53 gene from microdissected tissue: application to archival tumor samples.";
Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
[21]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J., Lipsky P.E.;
"Bcl6 and P53 gene mutations in tonsillar B cells.";
Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
[22]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
Pinto E.M., Mendonca B.B., Latronico A.C.;
"Allelic variant in intron 9 of TP53 gene.";
Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
[23]
NUCLEAR LOCALIZATION SIGNAL.
PubMed=2156209 [NCBI, ExPASy, EBI, Israel, Japan]
Addison C., Jenkins J.R., Sturzbecher H.-W.;
"The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.";
Oncogene 5:423-426(1990).
[24]
PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
DOI=10.1073/pnas.87.12.4766; PubMed=2141171 [NCBI, ExPASy, EBI, Israel, Japan]
Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
"Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
[25]
PHOSPHORYLATION.
PubMed=1705009 [NCBI, ExPASy, EBI, Israel, Japan]
Samad A., Carroll R.B.;
"The tumor suppressor p53 is bound to RNA by a stable covalent linkage.";
Mol. Cell. Biol. 11:1598-1606(1991).
[26]
DEPHOSPHORYLATION BY PP2A.
PubMed=1848668 [NCBI, ExPASy, EBI, Israel, Japan]
Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
"Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen.";
Mol. Cell. Biol. 11:1996-2003(1991).
[27]
ALTERNATIVE SPLICING.
PubMed=8632903 [NCBI, ExPASy, EBI, Israel, Japan]
Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M., Gilbert D., Iggo R., Frebourg T.;
"The human tumour suppressor gene p53 is alternatively spliced in normal cells.";
Oncogene 12:813-818(1996).
[28]
O-GLYCOSYLATION.
PubMed=8632915 [NCBI, ExPASy, EBI, Israel, Japan]
Shaw P., Freeman J., Bovey R., Iggo R.;
"Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.";
Oncogene 12:921-930(1996).
[29]
SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E., Scheffner M., Del Sal G.;
"Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.";
EMBO J. 18:6462-6471(1999).
[30]
ACETYLATION AT LYS-373 AND LYS-382.
DOI=10.1006/jmbi.1999.3415; PubMed=10656795 [NCBI, ExPASy, EBI, Israel, Japan]
Abraham J., Kelly J., Thibault P., Benchimol S.;
"Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry.";
J. Mol. Biol. 295:853-864(2000).
[31]
INTERACTION WITH E4F1.
DOI=10.1038/sj.onc.1203250; PubMed=10644996 [NCBI, ExPASy, EBI, Israel, Japan]
Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J., Schneider C., Del Sal G.;
"p53 is involved in the p120E4F-mediated growth arrest.";
Oncogene 19:188-199(2000).
[32]
PHOSPHORYLATION AT THR-18.
DOI=10.1038/sj.onc.1203709; PubMed=10951572 [NCBI, ExPASy, EBI, Israel, Japan]
Lopez-Borges S., Lazo P.A.;
"The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein.";
Oncogene 19:3656-3664(2000).
[33]
REVIEW ON ZINC-BINDING PROPERTIES.
DOI=10.1089/15230860152542961; PubMed=11554448 [NCBI, ExPASy, EBI, Israel, Japan]
Hainaut P., Mann K.;
"Zinc binding and redox control of p53 structure and function.";
Antioxid. Redox Signal. 3:611-623(2001).
[34]
DEACETYLATION AT LYS-382 BY SIRT1.
DOI=10.1016/S0092-8674(01)00527-X; PubMed=11672523 [NCBI, ExPASy, EBI, Israel, Japan]
Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A.;
"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
Cell 107:149-159(2001).
[35]
MINIMAL REPRESSION DOMAIN.
DOI=10.1074/jbc.M008231200; PubMed=11007800 [NCBI, ExPASy, EBI, Israel, Japan]
Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
"p53 amino acids 339-346 represent the minimal p53 repression domain.";
J. Biol. Chem. 276:1510-1515(2001).
[36]
SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-385; LYS-386; THR-387 AND GLU-388.
DOI=10.1074/jbc.M009476200; PubMed=11124955 [NCBI, ExPASy, EBI, Israel, Japan]
Rodriguez M.S., Dargemont C., Hay R.T.;
"SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.";
J. Biol. Chem. 276:12654-12659(2001).
[37]
PHOSPHORYLATION BY PRPK.
DOI=10.1074/jbc.M105669200; PubMed=11546806 [NCBI, ExPASy, EBI, Israel, Japan]
Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N., Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
"Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes.";
J. Biol. Chem. 276:44003-44011(2001).
[38]
PHOSPHORYLATION AT SER-392.
DOI=10.1016/S1097-2765(01)00176-9; PubMed=11239457 [NCBI, ExPASy, EBI, Israel, Japan]
Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R., Lozano G., Zhao Y., Lu H.;
"A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.";
Mol. Cell 7:283-292(2001).
[39]
INTERACTION WITH USP7.
DOI=10.1016/S0092-8674(02)01199-6; PubMed=12507430 [NCBI, ExPASy, EBI, Israel, Japan]
Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E., Shi Y.;
"Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.";
Cell 111:1041-1054(2002).
[40]
IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
DOI=10.1074/jbc.M108535200; PubMed=11706030 [NCBI, ExPASy, EBI, Israel, Japan]
Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
"Differential effect of ik3-1/cables on p53- and p73-induced cell death.";
J. Biol. Chem. 277:2951-2957(2002).
[41]
INTERACTION WITH HIPK2.
DOI=10.1074/jbc.M200153200; PubMed=11925430 [NCBI, ExPASy, EBI, Israel, Japan]
Kim E.-J., Park J.-S., Um S.-J.;
"Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.";
J. Biol. Chem. 277:32020-32028(2002).
[42]
INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46 AND LYS-382.
DOI=10.1038/ncb715; PubMed=11740489 [NCBI, ExPASy, EBI, Israel, Japan]
Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W., Will H., Schmitz M.L.;
"Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.";
Nat. Cell Biol. 4:1-10(2002).
[43]
INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
DOI=10.1038/ncb714; PubMed=11780126 [NCBI, ExPASy, EBI, Israel, Japan]
D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., Soddu S.;
"Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.";
Nat. Cell Biol. 4:11-19(2002).
[44]
INTERACTION WITH ING4.
PubMed=12750254 [NCBI, ExPASy, EBI, Israel, Japan]
Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., Harris C.C.;
"p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
Cancer Res. 63:2373-2378(2003).
[45]
ACETYLATION AT LYS-305.
DOI=10.1074/jbc.M212574200; PubMed=12724314 [NCBI, ExPASy, EBI, Israel, Japan]
Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
"Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305.";
J. Biol. Chem. 278:25568-25576(2003).
[46]
INTERACTION WITH P53DINP1.
DOI=10.1074/jbc.M301979200; PubMed=12851404 [NCBI, ExPASy, EBI, Israel, Japan]
Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B., Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
"TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity.";
J. Biol. Chem. 278:37722-37729(2003).
[47]
NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
DOI=10.1128/MCB.23.18.6396-6405.2003; PubMed=12944468 [NCBI, ExPASy, EBI, Israel, Japan]
O'Keefe K., Li H., Zhang Y.;
"Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination.";
Mol. Cell. Biol. 23:6396-6405(2003).
[48]
INTERACTION WITH HIPK1.
DOI=10.1073/pnas.0530308100; PubMed=12702766 [NCBI, ExPASy, EBI, Israel, Japan]
Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A., Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W., Mak T.W., Thukral S.K.;
"Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
[49]
INTERACTION WITH CDKN2AIP.
DOI=10.1042/BJ20040337; PubMed=15109303 [NCBI, ExPASy, EBI, Israel, Japan]
Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R., Kaul S.C.;
"Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.";
Biochem. J. 380:605-610(2004).
[50]
INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
DOI=10.1016/j.cell.2004.05.009; PubMed=15186775 [NCBI, ExPASy, EBI, Israel, Japan]
An W., Kim J., Roeder R.G.;
"Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.";
Cell 117:735-748(2004).
[51]
PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH TAF1.
DOI=10.1016/S1097-2765(04)00123-6; PubMed=15053879 [NCBI, ExPASy, EBI, Israel, Japan]
Li H.-H., Li A.G., Sheppard H.M., Liu X.;
"Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression.";
Mol. Cell 13:867-878(2004).
[52]
METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
DOI=10.1038/nature03117; PubMed=15525938 [NCBI, ExPASy, EBI, Israel, Japan]
Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D.;
"Regulation of p53 activity through lysine methylation.";
Nature 432:353-360(2004).
[53]
INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-15.
DOI=10.1074/jbc.M413200200; PubMed=15701641 [NCBI, ExPASy, EBI, Israel, Japan]
Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S., Chattopadhyay S.;
"Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif.";
J. Biol. Chem. 280:16019-16029(2005).
[54]
INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
DOI=10.1074/jbc.M505590200; PubMed=16219768 [NCBI, ExPASy, EBI, Israel, Japan]
Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
"WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.";
J. Biol. Chem. 280:43100-43108(2005).
[55]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-392, AND MASS SPECTROMETRY.
DOI=10.1021/pr050048h; PubMed=16083285 [NCBI, ExPASy, EBI, Israel, Japan]
Kim J.-E., Tannenbaum S.R., White F.M.;
"Global phosphoproteome of HT-29 human colon adenocarcinoma cells.";
J. Proteome Res. 4:1339-1346(2005).
[56]
INTERACTION WITH YWHAZ.
DOI=10.1016/j.febslet.2005.12.024; PubMed=16376338 [NCBI, ExPASy, EBI, Israel, Japan]
Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
"Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon.";
FEBS Lett. 580:305-310(2006).
[57]
METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
DOI=10.1038/nature05287; PubMed=17108971 [NCBI, ExPASy, EBI, Israel, Japan]
Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M., Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
"Repression of p53 activity by Smyd2-mediated methylation.";
Nature 444:629-632(2006).
[58]
MOTIF, AND METHYLATION AT LYS-372.
DOI=10.1038/nsmb1045; PubMed=16415881 [NCBI, ExPASy, EBI, Israel, Japan]
Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
"Structural basis for the methylation site specificity of SET7/9.";
Nat. Struct. Mol. Biol. 13:140-146(2006).
[59]
UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
DOI=10.1038/sj.emboj.7601490; PubMed=17170702 [NCBI, ExPASy, EBI, Israel, Japan]
Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K., Nakajima T.;
"Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'.";
EMBO J. 26:113-122(2007).
[60]
INTERACTION WITH ARMC10.
DOI=10.1016/j.febslet.2007.09.025; PubMed=17904127 [NCBI, ExPASy, EBI, Israel, Japan]
Zhou X., Yang G., Huang R., Chen X., Hu G.;
"SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53.";
FEBS Lett. 581:4943-4948(2007).
[61]
PHOSPHORYLATION AT SER-9.
DOI=10.1016/j.febslet.2007.11.022; PubMed=18022393 [NCBI, ExPASy, EBI, Israel, Japan]
Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
"Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9.";
FEBS Lett. 581:5649-5657(2007).
[62]
FUNCTION, AND INTERACTION WITH MAML1.
DOI=10.1074/jbc.M608974200; PubMed=17317671 [NCBI, ExPASy, EBI, Israel, Japan]
Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y., Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A., Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L., Wu L., Griffin J.D., Wazer D.E., Band H., Band V.;
"The notch regulator MAML1 interacts with p53 and functions as a coactivator.";
J. Biol. Chem. 282:11969-11981(2007).
[63]
DEMETHYLATION BY KDM1.
DOI=10.1038/nature06092; PubMed=17805299 [NCBI, ExPASy, EBI, Israel, Japan]
Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
"p53 is regulated by the lysine demethylase LSD1.";
Nature 449:105-108(2007).
[64]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND MASS SPECTROMETRY.
DOI=10.1073/pnas.0611217104; PubMed=17287340 [NCBI, ExPASy, EBI, Israel, Japan]
Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;
"Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.";
Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
[65]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-99, AND MASS SPECTROMETRY.
DOI=10.1126/science.1140321; PubMed=17525332 [NCBI, ExPASy, EBI, Israel, Japan]
Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.";
Science 316:1160-1166(2007).
[66]
IDENTIFICATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
Colinge J., Superti-Furga G., Bennett K.L.;
Submitted (OCT-2008) to UniProtKB.
[67]
STRUCTURE BY NMR OF 319-360.
DOI=10.1126/science.8023159; PubMed=8023159 [NCBI, ExPASy, EBI, Israel, Japan]
Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M.;
"High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.";
Science 265:386-391(1994).
[68]
STRUCTURE BY NMR OF 325-355.
DOI=10.1038/nsb1294-877; PubMed=7773777 [NCBI, ExPASy, EBI, Israel, Japan]
Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
"Solution structure of the tetrameric minimum transforming domain of p53.";
Nat. Struct. Biol. 1:877-890(1994).
[69]
STRUCTURE BY NMR OF 326-354.
DOI=10.1093/emboj/16.20.6230; PubMed=9321402 [NCBI, ExPASy, EBI, Israel, Japan]
McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J., Halazonetis T.D.;
"Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain.";
EMBO J. 16:6230-6236(1997).
[70]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
DOI=10.1126/science.8023157; PubMed=8023157 [NCBI, ExPASy, EBI, Israel, Japan]
Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.";
Science 265:346-355(1994).
[71]
X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
DOI=10.1126/science.7878469; PubMed=7878469 [NCBI, ExPASy, EBI, Israel, Japan]
Jeffrey P.D., Gorina S., Pavletich N.P.;
"Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.";
Science 267:1498-1502(1995).
[72]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
DOI=10.1126/science.274.5289.948; PubMed=8875929 [NCBI, ExPASy, EBI, Israel, Japan]
Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P.;
"Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.";
Science 274:948-953(1996).
[73]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
DOI=10.1126/science.274.5289.1001; PubMed=8875926 [NCBI, ExPASy, EBI, Israel, Japan]
Gorina S., Pavletich N.P.;
"Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.";
Science 274:1001-1005(1996).
[74]
X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7, AND INTERACTION WITH USP7.
DOI=10.1038/nsmb1067; PubMed=16474402 [NCBI, ExPASy, EBI, Israel, Japan]
Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H., Frappier L.;
"Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
Nat. Struct. Mol. Biol. 13:285-291(2006).
[75]
X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION WITH USP7.
DOI=10.1371/journal.pbio.0040027; PubMed=16402859 [NCBI, ExPASy, EBI, Israel, Japan]
Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
"Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
PLoS Biol. 4:228-239(2006).
[76]
REVIEW.
DOI=10.1126/science.8266092; PubMed=8266092 [NCBI, ExPASy, EBI, Israel, Japan]
Harris C.C.;
"p53: at the crossroads of molecular carcinogenesis and risk assessment.";
Science 262:1980-1981(1993).
[77]
REVIEW ON VARIANTS.
DOI=10.1126/science.1905840; PubMed=1905840 [NCBI, ExPASy, EBI, Israel, Japan]
Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
"p53 mutations in human cancers.";
Science 253:49-53(1991).
[78]
REVIEW ON VARIANTS.
DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5; PubMed=8829653 [NCBI, ExPASy, EBI, Israel, Japan]
de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H., Liao D., Soussi T., Kovach J.S., Sommer S.S.;
"Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses.";
Hum. Mutat. 7:202-213(1996).
[79]
VARIANT PRO-72.
DOI=10.1007/BF00201836; PubMed=1999338 [NCBI, ExPASy, EBI, Israel, Japan]
Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
"Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population.";
Hum. Genet. 86:369-370(1991).
[80]
VARIANT LFS THR-133.
PubMed=1933902 [NCBI, ExPASy, EBI, Israel, Japan]
Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
"A germ line mutation in exon 5 of the p53 gene in an extended cancer family.";
Cancer Res. 51:6385-6387(1991).
[81]
VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
DOI=10.1126/science.1978757; PubMed=1978757 [NCBI, ExPASy, EBI, Israel, Japan]
Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H.;
"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.";
Science 250:1233-1238(1990).
[82]
VARIANT LFS ASP-245.
DOI=10.1038/348747a0; PubMed=2259385 [NCBI, ExPASy, EBI, Israel, Japan]
Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.";
Nature 348:747-749(1990).
[83]
VARIANT LFS LEU-272.
PubMed=1737852 [NCBI, ExPASy, EBI, Israel, Japan]
Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J., Knutsen T., Minna J.D.;
"Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.";
J. Clin. Invest. 89:640-647(1992).
[84]
VARIANTS LFS HIS-273 AND VAL-325.
PubMed=1565144 [NCBI, ExPASy, EBI, Israel, Japan]
Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H., Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J., Strong L.C.;
"Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.";
N. Engl. J. Med. 326:1309-1315(1992).
[85]
VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
PubMed=1694291 [NCBI, ExPASy, EBI, Israel, Japan]
Bartek J., Iggo R., Gannon J., Lane D.P.;
"Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.";
Oncogene 5:893-899(1990).
[86]
VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
DOI=10.1073/pnas.87.19.7555; PubMed=1699228 [NCBI, ExPASy, EBI, Israel, Japan]
Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F., Gannon J.V., Lane D.P.;
"p53 mutations in colorectal cancer.";
Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
[87]
VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND SER-278.
DOI=10.1073/pnas.87.24.9958; PubMed=2263646 [NCBI, ExPASy, EBI, Israel, Japan]
Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
"Frequent mutation of the p53 gene in human esophageal cancer.";
Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
[88]
VARIANTS SPORADIC CANCERS.
DOI=10.1016/0006-291X(91)90623-F; PubMed=1647768 [NCBI, ExPASy, EBI, Israel, Japan]
Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R., Wakui A., Yamazaki T.;
"Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors.";
Biochem. Biophys. Res. Commun. 177:901-906(1991).
[89]
VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND HIS-273.
PubMed=1868473 [NCBI, ExPASy, EBI, Israel, Japan]
Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B., Roth J.A.;
"p53 gene mutations in Barrett's epithelium and esophageal cancer.";
Cancer Res. 51:4495-4499(1991).
[90]
VARIANTS SPORADIC CANCERS IN CHINA.
DOI=10.1038/350427a0; PubMed=1849234 [NCBI, ExPASy, EBI, Israel, Japan]
Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
"Mutational hotspot in the p53 gene in human hepatocellular carcinomas.";
Nature 350:427-428(1991).
[91]
VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
DOI=10.1038/350429a0; PubMed=1672732 [NCBI, ExPASy, EBI, Israel, Japan]
Bressac B., Kew M., Wands J., Ozturk M.;
"Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.";
Nature 350:429-431(1991).
[92]
VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
PubMed=1394225 [NCBI, ExPASy, EBI, Israel, Japan]
Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., Casey G.;
"Frequent p53 mutations in head and neck cancer.";
Cancer Res. 52:5997-6000(1992).
[93]
VARIANTS SPORADIC CANCERS.
PubMed=1327751 [NCBI, ExPASy, EBI, Israel, Japan]
Crook T., Vousden K.H.;
"Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.";
EMBO J. 11:3935-3940(1992).
[94]
VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
DOI=10.1002/ijc.2910520606; PubMed=1459726 [NCBI, ExPASy, EBI, Israel, Japan]
Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S., Yamamoto H., Tsuchida N.;
"The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma.";
Int. J. Cancer 52:867-872(1992).
[95]
VARIANT PRO-HIS-PRO-178 INS.
DOI=10.1093/hmg/1.3.207; PubMed=1303181 [NCBI, ExPASy, EBI, Israel, Japan]
Bhatia K., Guiterrez M.I., Magrath I.T.;
"A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
Hum. Mol. Genet. 1:207-208(1992).
[96]
VARIANTS SPORADIC CANCERS.
PubMed=1437144 [NCBI, ExPASy, EBI, Israel, Japan]
Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E., Appella E., May P.;
"p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.";
Oncogene 7:2161-2167(1992).
[97]
VARIANT SPORADIC CANCER THR-280.
DOI=10.1073/pnas.89.14.6516; PubMed=1631151 [NCBI, ExPASy, EBI, Israel, Japan]
Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Chen I.-H., Cao Y., Yao K.-T., Colburn N.H.;
"An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma.";
Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
[98]
VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220; GLN-248; LEU-248 AND HIS-273.
PubMed=7682763 [NCBI, ExPASy, EBI, Israel, Japan]
Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
"p53 alterations in human squamous cell carcinomas and carcinoma cell lines.";
Am. J. Pathol. 142:1131-1139(1993).
[99]
VARIANTS SPORADIC CANCERS.
PubMed=8402617 [NCBI, ExPASy, EBI, Israel, Japan]
Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
"The incidence of p53 mutations increases with progression of head and neck cancer.";
Cancer Res. 53:4477-4480(1993).
[100]
VARIANTS SPORADIC CANCERS.
PubMed=8336944 [NCBI, ExPASy, EBI, Israel, Japan]
Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
"Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors.";
Oncogene 8:2213-2220(1993).
[101]
VARIANTS, AND INVOLVEMENT IN LFL.
PubMed=8118819 [NCBI, ExPASy, EBI, Israel, Japan]
Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A., Kelsey A.M., Harris M., Jones P.H., Binchy A., Crowther D., Craft A.W., Eden O.B., Evans D.G.R., Thompson E., Mann J.R., Martin J., Mitchell E.L.D., Santibanez-Koref M.F.;
"Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.";
Cancer Res. 54:1298-1304(1994).
[102]
CHARACTERIZATION OF VARIANT ALA-143.
PubMed=8013454 [NCBI, ExPASy, EBI, Israel, Japan]
Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
"A temperature-sensitive mutant of human p53.";
EMBO J. 13:2535-2544(1994).
[103]
VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
PubMed=7887414 [NCBI, ExPASy, EBI, Israel, Japan]
Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M., Fraumeni J.F. Jr., Li F.P., Friend S.H.;
"Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
Am. J. Hum. Genet. 56:608-615(1995).
[104]
VARIANTS, AND INVOLVEMENT IN LFL.
PubMed=8718514 [NCBI, ExPASy, EBI, Israel, Japan]
Eeles R.A.;
"Germline mutations in the TP53 gene.";
Cancer Surv. 25:101-124(1995).
[105]
VARIANT LFS HIS-175.
PubMed=8825920 [NCBI, ExPASy, EBI, Israel, Japan]
Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D., Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M., Evans D.G.R.;
"An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53.";
J. Med. Genet. 32:942-945(1995).
[106]
VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND GLN-286.
DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0; PubMed=8829627 [NCBI, ExPASy, EBI, Israel, Japan]
Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B., Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
"Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
Hum. Mutat. 7:109-113(1996).
[107]
VARIANTS SPORADIC CANCERS.
DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; PubMed=9101296 [NCBI, ExPASy, EBI, Israel, Japan]
Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V., Zeuthen J.;
"Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer.";
Hum. Mutat. 9:348-355(1997).
[108]
VARIANT SPORADIC CANCER ILE-157.
DOI=10.1038/sj.onc.1201668; PubMed=9419979 [NCBI, ExPASy, EBI, Israel, Japan]
Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y., Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
"Drastic genetic instability of tumors and normal tissues in Turcot syndrome.";
Oncogene 15:2877-2881(1997).
[109]
VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273 AND SER-278.
DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G; PubMed=9450901 [NCBI, ExPASy, EBI, Israel, Japan]
van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J., Raubenheimer E.J.;
"Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample.";
Hum. Mutat. 11:39-44(1998).
[110]
VARIANT NON-CLASSICAL LFS CYS-337.
PubMed=9452042 [NCBI, ExPASy, EBI, Israel, Japan]
Luca J.W., Strong L.C., Hansen M.F.;
"A germline missense mutation R337C in exon 10 of the human p53 gene.";
Hum. Mutat. Suppl. 1:S58-S61(1998).
[111]
VARIANT LFS ILE-292.
DOI=10.1016/S0165-4608(98)00276-3; PubMed=10484981 [NCBI, ExPASy, EBI, Israel, Japan]
Gueran S., Tunca Y., Imirzalioglu N.;
"Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family.";
Cancer Genet. Cytogenet. 113:145-151(1999).
[112]
VARIANTS.
PubMed=10549356 [NCBI, ExPASy, EBI, Israel, Japan]
Hainaut P., Hollstein M.;
"p53 and human cancer: the first ten thousand mutations.";
Adv. Cancer Res. 77:81-137(2000).
[113]
VARIANT ADCC HIS-337.
DOI=10.1073/pnas.161479898; PubMed=11481490 [NCBI, ExPASy, EBI, Israel, Japan]
Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., Stratakis C.A., Sandrini R.;
"An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.";
Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
[114]
INVOLVEMENT IN CHOROID PLEXUS PAPILLOMA.
DOI=10.1038/sj.bjc.6600269; PubMed=12085209 [NCBI, ExPASy, EBI, Israel, Japan]
Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P., Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
"Investigations on a clinically and functionally unusual and novel germline p53 mutation.";
Br. J. Cancer 86:1592-1596(2002).
[115]
VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281.
DOI=10.1126/science.1133427; PubMed=16959974 [NCBI, ExPASy, EBI, Israel, Japan]
Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E.;
"The consensus coding sequences of human breast and colorectal cancers.";
Science 314:268-274(2006).
[116]
VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195; MET-216; ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
DOI=10.1186/bcr1637; PubMed=17224074 [NCBI, ExPASy, EBI, Israel, Japan]
Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
"Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas.";
Breast Cancer Res. 9:R5-R5(2007).
[117]
VARIANTS.
DOI=10.1002/humu.20495; PubMed=17311302 [NCBI, ExPASy, EBI, Israel, Japan]
Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M.;
"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.";
Hum. Mutat. 28:622-629(2007).
Comments
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
X02469; CAA26306.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13121; AAA59987.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13112; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13113; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13114; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13115; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13116; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13117; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13118; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13119; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M13120; AAA59987.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
K03199; AAA59989.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M14694; AAA61211.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M14695; AAA61212.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22898; AAA59988.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22882; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22883; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22884; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22887; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22888; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22894; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22895; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22896; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
M22897; AAA59988.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X01405; CAA25652.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60011; CAA42626.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60012; CAA42627.1; ALT_TERM; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60013; CAA42628.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60014; CAA42629.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60015; CAA42630.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60016; CAA42631.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60017; CAA42632.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60018; CAA42633.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60019; CAA42634.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X60020; CAA42635.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF135121; AAD28535.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF135120; AAD28535.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF307851; AAG28785.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
X54156; CAA38095.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
U94788; AAC12971.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF136271; AAD28628.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF136270; AAD28628.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AB082923; BAC16799.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY838896; AAV80424.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
BC003596; AAH03596.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY429684; AAR10356.1; -; mRNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY390341; AAQ90158.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY359814; AAR13239.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
U63714; AAB39322.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209136; AAF36362.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209128; AAF36354.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209129; AAF36355.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209130; AAF36356.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209131; AAF36357.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209132; AAF36358.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209133; AAF36359.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209134; AAF36360.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209135; AAF36361.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209148; AAF36374.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209149; AAF36375.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209150; AAF36376.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209151; AAF36377.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209152; AAF36378.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209153; AAF36379.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209154; AAF36380.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209155; AAF36381.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF209156; AAF36382.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF210309; AAF63442.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF210308; AAF63442.1; JOINED; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF210310; AAF63443.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF240684; AAK76358.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF240685; AAK76359.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AY270155; AAP30003.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
IPI IPI00025087; -.
IPI00375319; -.
PIR A25224; DNHU53.
RefSeq NP_000537.3; -.
NP_001119584.1; -.
UniGene Hs.654481
3D structure databases
PDB
1A1U; NMR; -; A/C=324-358.[ExPASy / RCSB / EBI]
1AIE; X-ray; 1.50 A; A=326-356.[ExPASy / RCSB / EBI]
1C26; X-ray; 1.70 A; A=325-356.[ExPASy / RCSB / EBI]
1DT7; NMR; -; X/Y=367-388.[ExPASy / RCSB / EBI]
1GZH; X-ray; 2.60 A; A=95-292, C=95-292.[ExPASy / RCSB / EBI]
1H26; X-ray; 2.24 A; E=376-386.[ExPASy / RCSB / EBI]
1HS5; NMR; -; A/B=324-357.[ExPASy / RCSB / EBI]
1JSP; NMR; -; A=367-386.[ExPASy / RCSB / EBI]
1KZY; X-ray; 2.50 A; A/B=95-289.[ExPASy / RCSB / EBI]
1MA3; X-ray; 2.00 A; B=372-389.[ExPASy / RCSB / EBI]
1OLG; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1OLH; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1PES; NMR; -; A/B/C/D=325-355.[ExPASy / RCSB / EBI]
1PET; NMR; -; A/B/C/D=325-355.[ExPASy / RCSB / EBI]
1SAE; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1SAF; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1SAH; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1SAJ; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1SAK; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1SAL; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
1TSR; X-ray; 2.20 A; A/B/C=94-312.[ExPASy / RCSB / EBI]
1TUP; X-ray; 2.20 A; A/B/C=94-312.[ExPASy / RCSB / EBI]
1UOL; X-ray; 1.90 A; A/B=94-312.[ExPASy / RCSB / EBI]
1XQH; X-ray; 1.75 A; B/F=369-377.[ExPASy / RCSB / EBI]
1YC5; X-ray; 1.40 A; B=372-389.[ExPASy / RCSB / EBI]
1YCQ; X-ray; 2.30 A; B=13-29.[ExPASy / RCSB / EBI]
1YCR; X-ray; 2.60 A; B=15-29.[ExPASy / RCSB / EBI]
1YCS; X-ray; 2.20 A; A=94-292.[ExPASy / RCSB / EBI]
2AC0; X-ray; 1.80 A; A/B/C/D=94-293.[ExPASy / RCSB / EBI]
2ADY; X-ray; 2.50 A; A/B=94-293.[ExPASy / RCSB / EBI]
2AHI; X-ray; 1.85 A; A/B/C/D=94-293.[ExPASy / RCSB / EBI]
2ATA; X-ray; 2.20 A; A/B/C/D=94-293.[ExPASy / RCSB / EBI]
2B3G; X-ray; 1.60 A; B=33-60.[ExPASy / RCSB / EBI]
2BIM; X-ray; 1.98 A; A/B=94-312.[ExPASy / RCSB / EBI]
2BIN; X-ray; 1.90 A; A=94-312.[ExPASy / RCSB / EBI]
2BIO; X-ray; 1.90 A; A=94-312.[ExPASy / RCSB / EBI]
2BIP; X-ray; 1.80 A; A=94-312.[ExPASy / RCSB / EBI]
2BIQ; X-ray; 1.80 A; A=94-312.[ExPASy / RCSB / EBI]
2F1X; X-ray; 2.30 A; A/B=360-368.[ExPASy / RCSB / EBI]
2FEJ; NMR; -; A=94-297.[ExPASy / RCSB / EBI]
2FOJ; X-ray; 1.60 A; B=363-367.[ExPASy / RCSB / EBI]
2FOO; X-ray; 2.20 A; B=358-363.[ExPASy / RCSB / EBI]
2GS0; NMR; -; B=20-71.[ExPASy / RCSB / EBI]
2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.[ExPASy / RCSB / EBI]
2H2D; X-ray; 1.70 A; B=372-389.[ExPASy / RCSB / EBI]
2H2F; X-ray; 2.20 A; B=372-389.[ExPASy / RCSB / EBI]
2H4F; X-ray; 2.00 A; D=372-389.[ExPASy / RCSB / EBI]
2H4H; X-ray; 1.99 A; B=372-389.[ExPASy / RCSB / EBI]
2H4J; X-ray; 2.10 A; D=372-389.[ExPASy / RCSB / EBI]
2H59; X-ray; 1.90 A; D/E=372-389.[ExPASy / RCSB / EBI]
2J0Z; NMR; -; A/B/C/D=326-356.[ExPASy / RCSB / EBI]
2J10; NMR; -; A/B/C/D=326-356.[ExPASy / RCSB / EBI]
2J11; NMR; -; A/B/C/D=332-356.[ExPASy / RCSB / EBI]
2J1W; X-ray; 1.80 A; A/B=94-312.[ExPASy / RCSB / EBI]
2J1X; X-ray; 1.65 A; A/B=94-312.[ExPASy / RCSB / EBI]
2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.[ExPASy / RCSB / EBI]
2J1Z; X-ray; 1.80 A; A/B=94-312.[ExPASy / RCSB / EBI]
2J20; X-ray; 1.80 A; A/B=94-312.[ExPASy / RCSB / EBI]
2J21; X-ray; 1.60 A; A/B=94-312.[ExPASy / RCSB / EBI]
2K8F; NMR; -; B=1-39.[ExPASy / RCSB / EBI]
2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.[ExPASy / RCSB / EBI]
2PCX; X-ray; 1.54 A; A=94-292.[ExPASy / RCSB / EBI]
2QVQ; X-ray; 2.00 A; A=94-289.[ExPASy / RCSB / EBI]
2QXA; X-ray; 1.50 A; A/B/C/D=95-289.[ExPASy / RCSB / EBI]
2QXB; X-ray; 2.50 A; A/B/C/D=95-289.[ExPASy / RCSB / EBI]
2QXC; X-ray; 1.85 A; A/B/C/D=95-289.[ExPASy / RCSB / EBI]
2VUK; X-ray; 1.50 A; A/B=94-312.[ExPASy / RCSB / EBI]
2Z5S; X-ray; 2.30 A; P/Q/R=15-29.[ExPASy / RCSB / EBI]
2Z5T; X-ray; 2.30 A; P/Q/R=15-29.[ExPASy / RCSB / EBI]
3D05; X-ray; 1.70 A; A=94-293.[ExPASy / RCSB / EBI]
3D06; X-ray; 1.20 A; A=94-293.[ExPASy / RCSB / EBI]
3D07; X-ray; 2.20 A; A/B=94-293.[ExPASy / RCSB / EBI]
3D08; X-ray; 1.40 A; A=94-293.[ExPASy / RCSB / EBI]
3D09; X-ray; 1.90 A; A=94-293.[ExPASy / RCSB / EBI]
3D0A; X-ray; 1.80 A; A/B/C/D=94-293.[ExPASy / RCSB / EBI]
3DAB; X-ray; 1.90 A; B/D/F/H=15-29.[ExPASy / RCSB / EBI]
3DAC; X-ray; 1.80 A; B/P=17-37.[ExPASy / RCSB / EBI]
3SAK; NMR; -; A/B/C/D=319-360.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1A1U; -.
1AIE; -.
1C26; -.
1DT7; -.
1GZH; -.
1H26; -.
1HS5; -.
1JSP; -.
1KZY; -.
1MA3; -.
1OLG; -.
1OLH; -.
1PES; -.
1PET; -.
1SAE; -.
1SAF; -.
1SAH; -.
1SAJ; -.
1SAK; -.
1SAL; -.
1TSR; -.
1TUP; -.
1UOL; -.
1XQH; -.
1YC5; -.
1YCQ; -.
1YCR; -.
1YCS; -.
2AC0; -.
2ADY; -.
2AHI; -.
2ATA; -.
2B3G; -.
2BIM; -.
2BIN; -.
2BIO; -.
2BIP; -.
2BIQ; -.
2F1X; -.
2FEJ; -.
2FOJ; -.
2FOO; -.
2GS0; -.
2H1L; -.
2H2D; -.
2H2F; -.
2H4F; -.
2H4H; -.
2H4J; -.
2H59; -.
2J0Z; -.
2J10; -.
2J11; -.
2J1W; -.
2J1X; -.
2J1Y; -.
2J1Z; -.
2J20; -.
2J21; -.
2K8F; -.
2OCJ; -.
2PCX; -.
2QVQ; -.
2QXA; -.
2QXB; -.
2QXC; -.
2VUK; -.
2Z5S; -.
2Z5T; -.
3D05; -.
3D06; -.
3D07; -.
3D08; -.
3D09; -.
3D0A; -.
3DAB; -.
3DAC; -.
3SAK; -.
DisProt DP00086; -.
ModBase P04637.
Protein-protein interaction databases
DIP DIP:368N; -.
IntAct P04637; 137.
PTM databases
PhosphoSite P04637; -.
Enzyme and pathway databases
Pathway_Interaction_DB aurora_a_pathway; Aurora A signaling.
bard1pathway; BARD1 signaling events.
pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
hif1apathway; Hypoxic and oxygen homeostasis regulation of HIF-1-alpha.
p75ntrpathway; p75(NTR)-mediated signaling.
hdac_classiii_pathway; Signaling events mediated by HDAC Class III.
p38alphabetadownstreampathway; Signaling mediated by p38-alpha and p38-beta.
Reactome REACT_1538; Cell Cycle Checkpoints.
2D gel databases
SWISS-2DPAGE P04637; -.
Organism-specific databases
GeneCards GC17M007512; -.
HGNC HGNC:11998; TP53.
GenAtlas TP53.
HPA CAB002973; -.
MIM 133239; phenotype. [NCBI / EBI]
151623; phenotype. [NCBI / EBI]
161550; phenotype. [NCBI / EBI]
191170; gene+phenotype. [NCBI / EBI]
202300; phenotype. [NCBI / EBI]
211980; phenotype. [NCBI / EBI]
260500; phenotype. [NCBI / EBI]
275355; phenotype. [NCBI / EBI]
Orphanet 360; Glioblastoma.
524; Li-Fraumeni syndrome.
1333; Pancreatic carcinoma, familial.
2807; Papilloma of choroid plexus.
PharmGKB PA36679; -.
Gene expression databases
ArrayExpress P04637; -.
Bgee P04637; -.
GermOnline ENSG00000141510; Homo sapiens.
Ontologies
GO
GO:0005783; Cellular component: endoplasmic reticulum (inferred from electronic annotation from UniProtKB-SubCell).
GO:0005626; Cellular component: insoluble fraction (inferred from direct assay from UniProtKB).
GO:0005739; Cellular component: mitochondrion (inferred from direct assay from UniProtKB).
GO:0016363; Cellular component: nuclear matrix (inferred from direct assay from UniProtKB).
GO:0005730; Cellular component: nucleolus (inferred from direct assay from UniProtKB).
GO:0016605; Cellular component: PML body (inferred from direct assay from UniProtKB).
GO:0005524; Molecular function: ATP binding (inferred from direct assay from UniProtKB).
GO:0051087; Molecular function: chaperone binding (inferred from physical interaction from UniProtKB).
GO:0003682; Molecular function: chromatin binding (inferred from direct assay from MGI).
GO:0005507; Molecular function: copper ion binding (inferred from direct assay from UniProtKB).
GO:0000739; Molecular function: DNA strand annealing activity (inferred from direct assay from UniProtKB).
GO:0019899; Molecular function: enzyme binding (inferred from physical interaction from UniProtKB).
GO:0046982; Molecular function: protein heterodimerization activity (inferred from physical interaction from UniProtKB).
GO:0047485; Molecular function: protein N-terminus binding (inferred from physical interaction from UniProtKB).
GO:0003700; Molecular function: transcription factor activity (inferred from direct assay from UniProtKB).
GO:0008270; Molecular function: zinc ion binding (traceable author statement from UniProtKB).
GO:0008635; Biological process: activation of caspase activity by cytochrome c (inferred from direct assay from UniProtKB).
GO:0006284; Biological process: base-excision repair (traceable author statement from UniProtKB).
GO:0007569; Biological process: cell aging (inferred from mutant phenotype from UniProtKB).
GO:0007050; Biological process: cell cycle arrest (traceable author statement from UniProtKB).
GO:0042149; Biological process: cellular response to glucose starvation (inferred from direct assay from MGI).
GO:0042771; Biological process: DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis (inferred from direct assay from MGI).
GO:0006983; Biological process: ER overload response (inferred from direct assay from MGI).
GO:0044419; Biological process: interspecies interaction between organisms (inferred from electronic annotation from UniProtKB-KW).
GO:0045786; Biological process: negative regulation of cell cycle (inferred from electronic annotation from UniProtKB-KW).
GO:0030308; Biological process: negative regulation of cell growth (inferred from mutant phenotype from UniProtKB).
GO:0051097; Biological process: negative regulation of helicase activity (traceable author statement from UniProtKB).
GO:0006289; Biological process: nucleotide-excision repair (inferred from mutant phenotype from UniProtKB).
GO:0010552; Biological process: positive regulation of specific transcription from RNA polymerase II promoter (inferred from direct assay from UniProtKB).
GO:0051262; Biological process: protein tetramerization (traceable author statement from UniProtKB).
GO:0046902; Biological process: regulation of mitochondrial membrane permeability (traceable author statement from UniProtKB).
GO:0002347; Biological process: response to tumor cell (inferred from electronic annotation from InterPro).
GO:0018144; Biological process: RNA-protein covalent cross-linking (inferred from electronic annotation from UniProtKB-KW).
GO:0006350; Biological process: transcription (inferred from electronic annotation from UniProtKB-KW).
QuickGo view.
Family and domain databases
InterPro IPR011615; p53_DNA_bd.
IPR012346; p53_RUNT_DNA_bd.
IPR010991; p53_tetrameristn.
IPR013872; p53_transactivation_domain.
IPR002117; p53_tumour_Ag.
IPR015551; Trp53.
Graphical view of domain structure.
Gene3D G3DSA:2.60.40.720; p53_RUNT_DNA_bd; 1.
G3DSA:4.10.170.10; p53_tetrameristn; 1.
PANTHER PTHR11447; Trp53; 1.
Pfam PF00870; P53; 1.
PF08563; P53_TAD; 1.
PF07710; P53_tetramer; 1.
Pfam graphical view of domain structure.
PRINTS PR00386; P53SUPPRESSR.
ProDom PD002681; P53; 1.
[Domain structure / List of seq. sharing at least 1 domain]
PROSITE PS00348; P53; 1.
Genome annotation databases
Ensembl ENSG00000141510; Homo sapiens. [Contig view]
GeneID 7157; -.
KEGG hsa:7157; -.
Phylogenomic databases
HOVERGEN P04637; -.
Other
PMAP-CutDB P04637; -.
SOURCE TP53; Homo sapiens.
ProtoNet P04637.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Acetylation; Activator; Alternative splicing; Anti-oncogene; Apoptosis; Cell cycle; Cytoplasm; Disease mutation; DNA-binding; Endoplasmic reticulum; Glycoprotein; Host-virus interaction; Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism; Transcription; Transcription regulation; Ubl conjugation; Zinc.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
CHAIN   1   393  393     Cellular tumor antigen p53. PRO_0000185703
DNA_BIND   102   292  191      
REGION   1    83  83     Interaction with HRMT1L2. 
REGION   1    44  44     Transcription activation (acidic). 
REGION   66   110  45     Interaction with WWOX. 
REGION   100   370  271     Interaction with HIPK1 (By similarity). 
REGION   116   292  177     Interaction with AXIN1 (By similarity). 
REGION   241   248  8     Interacts with the 53BP2 SH3 domain. 
REGION   256   294  39     Interaction with E4F1. 
REGION   300   393  94     Interaction with CARM1. 
REGION   319   360  42     Interaction with HIPK2. 
REGION   325   356  32     Oligomerization. 
REGION   359   363  5     Interaction with USP7. 
REGION   368   387  20     Basic (repression of DNA-binding). 
MOTIF   305   321  17     Bipartite nuclear localization signal. 
MOTIF   339   350  12     Nuclear export signal. 
MOTIF   370   372  3     [KR]-[STA]-K motif. 
METAL   176   176        Zinc. 
METAL   179   179        Zinc. 
METAL   238   238        Zinc. 
METAL   242   242        Zinc. 
MOD_RES   9     9        Phosphoserine; by HIPK4. 
MOD_RES   15    15        Phosphoserine; by PRPK. 
MOD_RES   18    18        Phosphothreonine; by VRK1. 
MOD_RES   46    46        Phosphoserine; by HIPK2. 
MOD_RES   55    55        Phosphothreonine; by TAF1. 
MOD_RES   99    99        Phosphoserine. 
MOD_RES   305   305        N6-acetyllysine. 
MOD_RES   315   315        Phosphoserine; by CDC2. 
MOD_RES   370   370        N6-methyllysine. 
MOD_RES   372   372        N6-methyllysine. 
MOD_RES   373   373        N6-acetyllysine. 
MOD_RES   382   382        N6-acetyllysine. 
MOD_RES   392   392        Phosphoserine; by CK2. 
CROSSLNK   386   386        Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO). 
VAR_SEQ   332   341        IRGRERFEMF -> DGTSFQKENC (in isoform 2). VSP_006535
VAR_SEQ   342   393        Missing (in isoform 2). VSP_006536
VARIANT   5     5  1     Q -> H (in a sporadic cancer; somatic mutation). VAR_044543 
VARIANT   6     6  1     S -> L (in a sporadic cancer; somatic mutation). VAR_044544 
VARIANT   7     7  1     D -> H (in a sporadic cancer; somatic mutation). VAR_005851 
VARIANT   8     8  1     P -> S (in a sporadic cancer; somatic mutation). VAR_044545 
VARIANT   10    10  1     V -> I (in a sporadic cancer; somatic mutation). VAR_044546 
VARIANT   11    11  1     E -> K (in sporadic cancers; somatic mutation). VAR_044547 
VARIANT   11    11  1     E -> Q (in sporadic cancers; somatic mutation). VAR_044548 
VARIANT   15    15  1     S -> R (in a sporadic cancer; somatic mutation). VAR_044549 
VARIANT   16    16  1     Q -> L (in a sporadic cancer; somatic mutation). VAR_044550 
VARIANT   17    17  1     E -> D (in a sporadic cancer; somatic mutation). VAR_044551 
VARIANT   24    24  1     K -> N (in a sporadic cancer; somatic mutation). VAR_044552 
VARIANT   28    28  1     E -> A (in a sporadic cancer; somatic mutation). VAR_044553 
VARIANT   29    30  2     NN -> KD (in a sporadic cancer; somatic mutation). VAR_047158
VARIANT   31    31  1     V -> I (in sporadic cancers; somatic mutation). VAR_044554 
VARIANT   33    33  1     S -> T (in a sporadic cancer; somatic mutation). VAR_044555 
VARIANT   34    34  1     P -> L (in a sporadic cancer; somatic mutation). VAR_044556 
VARIANT   35    35  1     L -> F (in sporadic cancers; somatic mutation). VAR_005852 
VARIANT   36    36  1     P -> L (in a sporadic cancer; somatic mutation). VAR_044557 
VARIANT   37    37  1     S -> P (in a sporadic cancer; somatic mutation). VAR_044558 
VARIANT   37    37  1     S -> T (in a sporadic cancer; somatic mutation). VAR_044559 
VARIANT   39    39  1     A -> P (in a sporadic cancer; somatic mutation). VAR_044560 
VARIANT   39    39  1     A -> V (in a sporadic cancer; somatic mutation). VAR_044561 
VARIANT   42    42  1     D -> Y (in a sporadic cancer; somatic mutation). VAR_044562 
VARIANT   43    43  1     L -> S (in a sporadic cancer; somatic mutation). VAR_005853 
VARIANT   44    44  1     M -> I (in a sporadic cancer; somatic mutation). VAR_044563 
VARIANT   44    44  1     M -> T (in a sporadic cancer; somatic mutation). VAR_044564 
VARIANT   44    44  1     M -> V (in a sporadic cancer; somatic mutation). VAR_044565 
VARIANT   45    45  1     L -> M (in a sporadic cancer; somatic mutation). VAR_044566 
VARIANT   46    46  1     S -> F (in sporadic cancers; somatic mutation). VAR_044567 
VARIANT   46    46  1     S -> P (in sporadic cancers; somatic mutation). VAR_044568 
VARIANT   47    47  1     P -> L (in sporadic cancers; somatic mutation). VAR_044569 
VARIANT   47    47  1     P -> S (in dbSNP:rs1800371 [NCBI]). VAR_014632 
VARIANT   48    48  1     D -> G (in a sporadic cancer; somatic mutation). VAR_044570 
VARIANT   49    49  1     D -> H (in sporadic cancers; somatic mutation). VAR_044571 
VARIANT   49    49  1     D -> N (in a sporadic cancer; somatic mutation). VAR_044572 
VARIANT   49    49  1     D -> Y (in sporadic cancers; somatic mutation). VAR_044573 
VARIANT   52    52  1     Q -> H (in a sporadic cancer; somatic mutation). VAR_044574 
VARIANT   53    53  1     W -> C (in sporadic cancers; somatic mutation). VAR_005854 
VARIANT   53    53  1     W -> G (in a sporadic cancer; somatic mutation). VAR_044575 
VARIANT   54    54  1     F -> L (in a sporadic cancer; somatic mutation). VAR_044576 
VARIANT   54    54  1     F -> Y (in a sporadic cancer; somatic mutation). VAR_044577 
VARIANT   56    56  1     E -> K (in sporadic cancers; somatic mutation). VAR_044578 
VARIANT   56    56  1     E -> V (in a sporadic cancer; somatic mutation). VAR_044579 
VARIANT   58    58  1     P -> Q (in a sporadic cancer; somatic mutation). VAR_044580 
VARIANT   58    58  1     P -> T (in a sporadic cancer; somatic mutation). VAR_044581 
VARIANT   59    59  1     G -> C (in sporadic cancers; somatic mutation). VAR_044582 
VARIANT   59    59  1     G -> D (in sporadic cancers; somatic mutation). VAR_044583 
VARIANT   59    59  1     G -> N (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions). VAR_045783 
VARIANT   60    60  1     P -> L (in sporadic cancers; somatic mutation). VAR_044584 
VARIANT   60    60  1     P -> Q (in a sporadic cancer; somatic mutation). VAR_044585 
VARIANT   60    60  1     P -> S (in a sporadic cancer; somatic mutation). VAR_005855 
VARIANT   61    61  1     D -> G (in sporadic cancers; somatic mutation). VAR_044586 
VARIANT   61    61  1     D -> N (in sporadic cancers; somatic mutation). VAR_044587 
VARIANT   62    62  1     E -> D (in a sporadic cancer; somatic mutation). VAR_044588 
VARIANT   63    63  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044589 
VARIANT   63    63  1     A -> V (in a sporadic cancer; somatic mutation). VAR_044590 
VARIANT   65    65  1     R -> T (in a sporadic cancer; somatic mutation). VAR_044591 
VARIANT   66    66  1     M -> I (in a sporadic cancer; somatic mutation). VAR_044592 
VARIANT   66    66  1     M -> R (in a sporadic cancer; somatic mutation). VAR_044593 
VARIANT   67    67  1     P -> L (in sporadic cancers; somatic mutation). VAR_044594 
VARIANT   67    67  1     P -> R (in a sporadic cancer; somatic mutation). VAR_044595 
VARIANT   67    67  1     P -> S (in sporadic cancers; somatic mutation). VAR_044596 
VARIANT   68    68  1     E -> G (in sporadic cancers; somatic mutation). VAR_044597 
VARIANT   68    68  1     E -> Q (in a sporadic cancer; somatic mutation). VAR_044598 
VARIANT   69    69  1     A -> D (in a sporadic cancer; somatic mutation). VAR_044599 
VARIANT   69    69  1     A -> G (in sporadic cancers; somatic mutation). VAR_044600 
VARIANT   69    69  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044601 
VARIANT   69    69  1     A -> V (in a sporadic cancer; somatic mutation). VAR_044602 
VARIANT   70    70  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044603 
VARIANT   71    71  1     P -> T (in a sporadic cancer; somatic mutation). VAR_044604 
VARIANT   72    72  1     R -> C (in sporadic cancers; somatic mutation). VAR_045784 
VARIANT   72    72  1     R -> G (in sporadic cancers; somatic mutation). VAR_045785 
VARIANT   72    72  1     R -> H (in sporadic cancers; somatic mutation). VAR_045786 
VARIANT   72    72  1     R -> L (in a sporadic cancer; somatic mutation). VAR_045787 
VARIANT   72    72  1     R -> P (in dbSNP:rs1042522 [NCBI]). VAR_005856 
VARIANT   73    73  1     V -> E (in a sporadic cancer; somatic mutation). VAR_044605 
VARIANT   73    73  1     V -> L (in sporadic cancers; somatic mutation). VAR_044606 
VARIANT   73    73  1     V -> M (in sporadic cancers; somatic mutation). VAR_044607 
VARIANT   74    74  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044608 
VARIANT   75    75  1     P -> L (in sporadic cancers; somatic mutation). VAR_044609 
VARIANT   75    75  1     P -> R (in sporadic cancers; somatic mutation). VAR_044610 
VARIANT   75    75  1     P -> S (in a sporadic cancer; somatic mutation). VAR_044611 
VARIANT   76    76  1     A -> G (in a sporadic cancer; somatic mutation). VAR_044612 
VARIANT   76    76  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044613 
VARIANT   77    77  1     P -> A (in sporadic cancers; somatic mutation). VAR_044614 
VARIANT   78    78  1     A -> V (in sporadic cancers; somatic mutation). VAR_044615 
VARIANT   79    79  1     A -> G (in a sporadic cancer; somatic mutation). VAR_044616 
VARIANT   79    79  1     A -> T (in a sporadic cancer; somatic mutation). VAR_005857 
VARIANT   79    79  1     A -> V (in sporadic cancers; somatic mutation). VAR_044617 
VARIANT   80    80  1     P -> L (in a sporadic cancer; somatic mutation). VAR_044618 
VARIANT   80    80  1     P -> S (in a sporadic cancer; somatic mutation). VAR_044619 
VARIANT   81    81  1     T -> I (in sporadic cancers; somatic mutation). VAR_044620 
VARIANT   82    82  1     P -> L (in LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044621 
VARIANT   82    82  1     P -> S (in sporadic cancers; somatic mutation). VAR_044622 
VARIANT   83    83  1     A -> E (in a sporadic cancer; somatic mutation). VAR_044623 
VARIANT   83    83  1     A -> V (in sporadic cancers; somatic mutation). VAR_044624 
VARIANT   84    84  1     A -> G (in sporadic cancers; somatic mutation). VAR_044625 
VARIANT   84    84  1     A -> V (in sporadic cancers; somatic mutation). VAR_044626 
VARIANT   85    85  1     P -> L (in sporadic cancers; somatic mutation). VAR_044627 
VARIANT   85    85  1     P -> S (in sporadic cancers; somatic mutation). VAR_044628 
VARIANT   86    86  1     A -> V (in a sporadic cancer; somatic mutation). VAR_044629 
VARIANT   87    87  1     P -> Q (in sporadic cancers; somatic mutation). VAR_005858 
VARIANT   88    88  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044630 
VARIANT   88    88  1     A -> V (in sporadic cancers; somatic mutation). VAR_044631 
VARIANT   89    89  1     P -> L (in sporadic cancers; somatic mutation). VAR_044632 
VARIANT   89    89  1     P -> S (in sporadic cancers; somatic mutation). VAR_044633 
VARIANT   90    90  1     S -> F (in sporadic cancers; somatic mutation). VAR_044634 
VARIANT   90    90  1     S -> Y (in a sporadic cancer; somatic mutation). VAR_044635 
VARIANT   91    91  1     W -> C (in a sporadic cancer; somatic mutation). VAR_044636 
VARIANT   92    92  1     P -> A (in a sporadic cancer; somatic mutation). VAR_044637 
VARIANT   92    92  1     P -> L (in a sporadic cancer; somatic mutation). VAR_044638 
VARIANT   92    92  1     P -> S (in a sporadic cancer; somatic mutation). VAR_044639 
VARIANT   93    93  1     L -> M (in a sporadic cancer; somatic mutation). VAR_044640 
VARIANT   93    93  1     L -> P (in a sporadic cancer; somatic mutation). VAR_044641 
VARIANT   94    94  1     S -> L (in sporadic cancers; somatic mutation). VAR_044642 [3D]
VARIANT   94    94  1     S -> T (in sporadic cancers; somatic mutation). VAR_005859 [3D]
VARIANT   95    95  1     S -> F (in sporadic cancers; somatic mutation). VAR_044643 [3D]
VARIANT   95    95  1     S -> T (in a sporadic cancer; somatic mutation). VAR_044644 [3D]
VARIANT   96    96  1     S -> C (in a sporadic cancer; somatic mutation). VAR_044645 [3D]
VARIANT   96    96  1     S -> F (in sporadic cancers; somatic mutation). VAR_044646 [3D]
VARIANT   96    96  1     S -> P (in a sporadic cancer; somatic mutation). VAR_044647 [3D]
VARIANT   97    97  1     V -> A (in a sporadic cancer; somatic mutation). VAR_044648 [3D]
VARIANT   97    97  1     V -> F (in a sporadic cancer; somatic mutation). VAR_044649 [3D]
VARIANT   97    97  1     V -> I (in familial cancer not matching LFS; germline mutation and in a sporadic cancer; somatic mutation). VAR_044650 [3D]
VARIANT   98    98  1     P -> L (in sporadic cancers; somatic mutation). VAR_044651 [3D]
VARIANT   98    98  1     P -> S (in sporadic cancers; somatic mutation). VAR_044652 [3D]
VARIANT   99    99  1     S -> F (in sporadic cancers; somatic mutation). VAR_044653 [3D]
VARIANT   99    99  1     S -> P (in a sporadic cancer; somatic mutation). VAR_044654 [3D]
VARIANT   100   100  1     Q -> R (in a sporadic cancer; somatic mutation). VAR_044655 [3D]
VARIANT   101   101  1     K -> N (in a sporadic cancer; somatic mutation). VAR_044656 [3D]
VARIANT   101   101  1     K -> R (in sporadic cancers; somatic mutation). VAR_044657 [3D]
VARIANT   102   102  1     T -> I (in sporadic cancers; somatic mutation). VAR_044658 [3D]
VARIANT   104   104  1     Q -> H (in sporadic cancers; somatic mutation). VAR_044659 [3D]
VARIANT   104   104  1     Q -> L (in a sporadic cancer; somatic mutation). VAR_044660 [3D]
VARIANT   105   105  1     G -> C (in LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044661 [3D]
VARIANT   105   105  1     G -> D (in sporadic cancers; somatic mutation). VAR_044662 [3D]
VARIANT   105   105  1     G -> R (in sporadic cancers; somatic mutation). VAR_044663 [3D]
VARIANT   105   105  1     G -> S (in a sporadic cancer; somatic mutation). VAR_044664 [3D]
VARIANT   105   105  1     G -> V (in sporadic cancers; somatic mutation). VAR_044665 [3D]
VARIANT   106   106  1     S -> G (in a sporadic cancer; somatic mutation). VAR_044666 [3D]
VARIANT   106   106  1     S -> R (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044667 [3D]
VARIANT   107   107  1     Y -> C (in a sporadic cancer; somatic mutation). VAR_044668 [3D]
VARIANT   107   107  1     Y -> D (in sporadic cancers; somatic mutation). VAR_044669 [3D]
VARIANT   107   107  1     Y -> H (in a sporadic cancer; somatic mutation). VAR_044670 [3D]
VARIANT   108   108  1     G -> D (in a sporadic cancer; somatic mutation). VAR_044671 [3D]
VARIANT   108   108  1     G -> S (in sporadic cancers; somatic mutation). VAR_044672 [3D]
VARIANT   109   109  1     F -> C (in sporadic cancers; somatic mutation). VAR_044673 [3D]
VARIANT   109   109  1     F -> L (in a sporadic cancer; somatic mutation). VAR_044674 [3D]
VARIANT   109   109  1     F -> S (in sporadic cancers; somatic mutation). VAR_044675 [3D]
VARIANT   110   110  1     R -> C (in sporadic cancers; somatic mutation). VAR_005860 [3D]
VARIANT   110   110  1     R -> G (in a sporadic cancer; somatic mutation). VAR_044676 [3D]
VARIANT   110   110  1     R -> H (in sporadic cancers; somatic mutation). VAR_044677 [3D]
VARIANT   110   110  1     R -> L (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_005861 [3D]
VARIANT   110   110  1     R -> P (in sporadic cancers; somatic mutation). VAR_005862 [3D]
VARIANT   110   110  1     R -> S (in a sporadic cancer; somatic mutation). VAR_044678 [3D]
VARIANT   111   111  1     L -> M (in a sporadic cancer; somatic mutation). VAR_044679 [3D]
VARIANT   111   111  1     L -> P (in sporadic cancers; somatic mutation). VAR_044680 [3D]
VARIANT   111   111  1     L -> Q (in sporadic cancers; somatic mutation). VAR_044681 [3D]
VARIANT   111   111  1     L -> R (in sporadic cancers; somatic mutation). VAR_044682 [3D]
VARIANT   112   112  1     G -> D (in sporadic cancers; somatic mutation). VAR_044683 [3D]
VARIANT   112   112  1     G -> S (in sporadic cancers; somatic mutation). VAR_044684 [3D]
VARIANT   113   113  1     F -> C (in sporadic cancers; somatic mutation). VAR_005863 [3D]
VARIANT   113   113  1     F -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions). VAR_045788 [3D]
VARIANT   113   113  1     F -> I (in a sporadic cancer; somatic mutation). VAR_044685 [3D]
VARIANT   113   113  1     F -> L (in sporadic cancers; somatic mutation). VAR_044686 [3D]
VARIANT   113   113  1     F -> S (in sporadic cancers; somatic mutation). VAR_044687 [3D]
VARIANT   113   113  1     F -> V (in sporadic cancers; somatic mutation). VAR_033033 [3D]
VARIANT   115   115  1     H -> Y (in sporadic cancers; somatic mutation). VAR_044688 [3D]
VARIANT   116   116  1     S -> C (in sporadic cancers; somatic mutation). VAR_044689 [3D]
VARIANT   116   116  1     S -> F (in a sporadic cancer; somatic mutation). VAR_044690 [3D]
VARIANT   116   116  1     S -> P (in a sporadic cancer; somatic mutation). VAR_044691 [3D]
VARIANT   117   117  1     G -> E (in sporadic cancers; somatic mutation). VAR_044692 [3D]
VARIANT   117   117  1     G -> R (in sporadic cancers; somatic mutation). VAR_044693 [3D]
VARIANT   118   118  1     T -> A (in a sporadic cancer; somatic mutation). VAR_044694 [3D]
VARIANT   118   118  1     T -> I (in sporadic cancers; somatic mutation). VAR_044695 [3D]
VARIANT   118   118  1     T -> R (in a sporadic cancer; somatic mutation). VAR_044696 [3D]
VARIANT   119   119  1     A -> D (in a sporadic cancer; somatic mutation). VAR_044697 [3D]
VARIANT   119   119  1     A -> T (in a sporadic cancer; somatic mutation). VAR_044698 [3D]
VARIANT   120   120  1     K -> E (in sporadic cancers; somatic mutation). VAR_044699 [3D]
VARIANT   120   120  1     K -> M (in sporadic cancers; somatic mutation). VAR_044700 [3D]
VARIANT   120   120  1     K -> Q (in a sporadic cancer; somatic mutation). VAR_044701 [3D]
VARIANT   120   120  1     K -> R (in sporadic cancers; somatic mutation). VAR_044702 [3D]
VARIANT   121   121  1     S -> F (in sporadic cancers; somatic mutation). VAR_044703 [3D]
VARIANT   122   122  1     V -> L (in a sporadic cancer; somatic mutation). VAR_044704 [3D]
VARIANT   123   123  1     T -> I (in a sporadic cancer; somatic mutation). VAR_044705 [3D]
VARIANT   123   123  1     T -> N (in a sporadic cancer; somatic mutation). VAR_044706 [3D]
VARIANT   124   124  1     C -> G (in a sporadic cancer; somatic mutation). VAR_044707 [3D]
VARIANT   124   124  1     C -> R (in sporadic cancers; somatic mutation). VAR_044708 [3D]
VARIANT   124   124  1     C -> S (in sporadic cancers; somatic mutation). VAR_044709 [3D]
VARIANT   124   124  1     C -> W (in a sporadic cancer; somatic mutation). VAR_044710 [3D]
VARIANT   124   124  1     C -> Y (in a sporadic cancer; somatic mutation). VAR_044711 [3D]
VARIANT   125   125  1     T -> A (in a sporadic cancer; somatic mutation). VAR_044712 [3D]
VARIANT   125   125  1     T -> K (in sporadic cancers; somatic mutation). VAR_044713 [3D]
VARIANT   125   125  1     T -> M (in sporadic cancers; somatic mutation). VAR_005864 [3D]
VARIANT   125   125  1     T -> P (in a sporadic cancer; somatic mutation). VAR_044714 [3D]
VARIANT   125   125  1     T -> R (in sporadic cancers; somatic mutation). VAR_044715 [3D]
VARIANT   126   126  1     Y -> C (in a familial cancer not matching LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044716 [3D]
VARIANT   126   126  1     Y -> D (in sporadic cancers; somatic mutation). VAR_005865 [3D]
VARIANT   126   126  1     Y -> F (in a sporadic cancer; somatic mutation). VAR_044717 [3D]
VARIANT   126   126  1     Y -> G (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions). VAR_045789 [3D]
VARIANT   126   126  1     Y -> H (in sporadic cancers; somatic mutation). VAR_044718 [3D]
VARIANT   126   126  1     Y -> N (in sporadic cancers; somatic mutation). VAR_005866 [3D]
VARIANT   126   126  1     Y -> S (in sporadic cancers; somatic mutation). VAR_044719 [3D]
VARIANT   127   127  1     S -> C (in a sporadic cancer; somatic mutation). VAR_044720 [3D]
VARIANT   127   127  1     S -> F (in sporadic cancers; somatic mutation). VAR_005867 [3D]
VARIANT   127   127  1     S -> P (in sporadic cancers; somatic mutation). VAR_044721 [3D]
VARIANT   127   127  1     S -> T (in sporadic cancers; somatic mutation). VAR_044722 [3D]
VARIANT   127   127  1     S -> Y (in sporadic cancers; somatic mutation). VAR_044723 [3D]
VARIANT   128   128  1     P -> A (in sporadic cancers; somatic mutation). VAR_044724 [3D]
VARIANT   128   128  1     P -> L (in sporadic cancers; somatic mutation). VAR_044725 [3D]
VARIANT   128   128  1     P -> R (in sporadic cancers; somatic mutation). VAR_044726 [3D]
VARIANT   128   128  1     P -> S (in sporadic cancers; somatic mutation). VAR_005868 [3D]
VARIANT   129   129  1     A -> D (in sporadic cancers; somatic mutation). VAR_005869 [3D]
VARIANT   129   129  1     A -> G (in a sporadic cancer; somatic mutation). VAR_044727 [3D]
VARIANT   129   129  1     A -> T (in sporadic cancers; somatic mutation). VAR_044728 [3D]
VARIANT   129   129  1     A -> V (in sporadic cancers; somatic mutation). VAR_044729 [3D]
VARIANT   130   130  1     L -> F (in sporadic cancers; somatic mutation). VAR_044730 [3D]
VARIANT   130   130  1     L -> H (in sporadic cancers; somatic mutation). VAR_044731 [3D]
VARIANT   130   130  1     L -> I (in a sporadic cancer; somatic mutation). VAR_044732 [3D]
VARIANT   130   130  1     L -> P (in sporadic cancers; somatic mutation). VAR_044733 [3D]
VARIANT   130   130  1     L -> R (in sporadic cancers; somatic mutation). VAR_005870 [3D]
VARIANT   130   130  1     L -> V (in sporadic cancers; somatic mutation). VAR_044734 [3D]
VARIANT   131   131  1     N -> D (in a sporadic cancer; somatic mutation). VAR_044735 [3D]
VARIANT   131   131  1     N -> H (in sporadic cancers; somatic mutation). VAR_044736 [3D]
VARIANT   131   131  1     N -> I (in sporadic cancers; somatic mutation). VAR_044737 [3D]
VARIANT   131   131  1     N -> K (in sporadic cancers; somatic mutation). VAR_005872 [3D]
VARIANT   131   131  1     N -> S (in sporadic cancers; somatic mutation). VAR_005871 [3D]
VARIANT   131   131  1     N -> T (in a sporadic cancer; somatic mutation). VAR_044738 [3D]
VARIANT   131   131  1     N -> Y (in sporadic cancers; somatic mutation). VAR_044739 [3D]
VARIANT   132   133  2     KM -> NL (in a sporadic cancer; somatic mutation). VAR_047159
VARIANT   132   132  1     K -> E (in LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044740 [3D]
VARIANT   132   132  1     K -> L (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions). VAR_045790 [3D]
VARIANT   132   132  1     K -> M (in sporadic cancers; somatic mutation). VAR_005873 [3D]
VARIANT   132   132  1     K -> N (in sporadic cancers; somatic mutation). VAR_044741 [3D]
VARIANT   132   132  1     K -> Q (in sporadic cancers; somatic mutation). VAR_005874 [3D]
VARIANT   132   132  1     K -> R (in sporadic cancers; somatic mutation). VAR_044742 [3D]
VARIANT   132   132  1     K -> T (in sporadic cancers; somatic mutation). VAR_044743 [3D]
VARIANT   132   132  1     K -> W (in a sporadic cancer; somatic mutation; requires 2 nucleotide substitutions). VAR_045791 [3D]
VARIANT   133   133  1     M -> I (in sporadic cancers; somatic mutation). VAR_044744 [3D]
VARIANT   133   133  1     M -> K (in sporadic cancers; somatic mutation). VAR_044745 [3D]
VARIANT   133   133  1     M -> L (in sporadic cancers; somatic mutation). VAR_044746 [3D]
VARIANT   133   133  1     M -> R (in LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_044747 [3D]
VARIANT   133   133  1     M -> T (in LFS; germline mutation and in sporadic cancers; somatic mutation). VAR_005875 [3D]
VARIANT   133   133  1     M -> V (in sporadic cancers; somatic mutation). VAR_044748 [3D]
VARIANT   134   134  1     F -> C (in sporadic cancers; somatic mutation). VAR_044749 [3D]
VARIANT   134   134  1     F -> I (in sporadic cancers; somatic mutation). VAR_044750 [3D]
VARIANT   134   134  1     F -> L (in sporadic cancers; somatic mutation). VAR_036504 [3D]
VARIANT   134   134  1     F -> S (in sporadic cancers; somatic mutation). VAR_044751 [3D]
VARIANT   134   134  1     F -> V (in sporadic cancers; somatic mutation). VAR_044752 [3D]
VARIANT   135   135  1     C -> F (in sporadic cancers; somatic mutation). VAR_005877 [3D]